

ISSN: 1674-0815

cjhmonline.com

DoI-10.564220/1674-0815

Chinese Journal of  
Health Management

Chinese Medical Association



## Natural Approaches to Menstrual Pain Management: A Review on Spirulina and Clove-Based Nutraceutical Formulations

Mrs. Vidya Umesh Patil \*

Department of Pharmacognosy, Ashokrao Mane College of Pharmacy, Peth Vadgaon, Kolhapur, India  
Corresponding Author Email id: [vidyapatil@amcoph.org](mailto:vidyapatil@amcoph.org)

### Article Information

Received: 13-12-2025

Revised: 08-01-2026

Accepted: 17-02-2026

Published: 28-03-2026

### Keywords

*Dysmenorrhea, Nutraceuticals, Spirulina, Clove, Herbal therapy, Natural analgesics, Women's health*

### ABSTRACT:

A number of women of childbearing age have dysmenorrhea, which is pain or discomfort during their periods. It can make things less fun and less productive. Most of the time, it's because there are too many prostaglandins, which make the uterus contract, become inflammatory, and ache. A lot of people take common medicines like non-steroidal anti-inflammatory pills (NSAIDs) and hormonal treatments, but they typically have adverse effects, aren't safe to use for a long time, and patients don't always follow them. In the past few years, people have been more interested in natural and nutraceutical solutions to treat dysmenorrhea because they are safer and last longer. Spirulina (*Arthrospira platensis*) and clove (*Syzygium aromaticum*) have garnered interest for their strong anti-inflammatory, antioxidant, and pain-relieving effects. Spirulina has a lot of bioactive compounds, such as phycocyanin and essential minerals. Eugenol, which is a well-known natural pain reliever and muscle relaxant, is found in clove. This review shows that spirulina and clove can both help with menstruation pain, either on their own or together. They do this via lowering oxidative stress, relaxing smooth muscle, and blocking prostaglandins. The findings suggest that spirulina clove-based nutraceutical formulations may offer a realistic, safe, and effective alternative for the therapy of dysmenorrhea, warranting further clinical validation and formulation enhancement.

©2026 The authors

This is an Open Access article

distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)



## 1. INTRODUCTION:

Dysmenorrhea, or menstrual discomfort, is one of the most frequent gynaecological problems that women of reproductive age have all over the world. Epidemiological studies show that between 45% and 95% of people have the disease, and a large number of them have moderate to severe pain that makes it hard to do everyday things, do well in school, and enjoy life in general<sup>1,2</sup>. Even though dysmenorrhea is quite common, it is often not reported enough or treated properly, especially in underdeveloped countries. Dysmenorrhea is often categorised into primary and secondary forms. Primary dysmenorrhea manifests without discernible pelvic disease and is frequently linked to ovulatory cycles, usually commencing in adolescence<sup>3</sup>. Secondary dysmenorrhea, on the other hand, is caused by underlying gynaecological problems including endometriosis, uterine fibroids, or pelvic inflammatory disease. It usually starts later in life and gets worse over time<sup>4</sup>. The pathophysiology of dysmenorrhea is mainly due to the increased production and release of uterine prostaglandins, especially prostaglandin F<sub>2α</sub> (PGF<sub>2α</sub>), during menstruation. High amounts of prostaglandins cause strong contractions in the uterus, less blood supply to the uterus, and ischaemia, which causes pain<sup>5</sup>. Inflammatory mediators such as cytokines and leukotrienes, in conjunction with oxidative stress, significantly intensify uterine hyperactivity and nociception<sup>6</sup>. These mechanisms together make menstrual discomfort worse and more likely to happen again. Traditional management approaches, such as non-steroidal anti-inflammatory medications (NSAIDs) and hormonal contraceptives, principally focus on inhibiting prostaglandin synthesis and suppressing ovulation. But using them for a long time might cause problems like stomach problems, hormonal abnormalities, and not being safe for some groups of people<sup>7</sup>. These restrictions show how important it is to find safer, cheaper, and better-tolerated alternative treatments. In this context, natural and nutraceutical treatments have garnered heightened interest due to their multifaceted mechanisms, encompassing anti-inflammatory, antioxidant, and antispasmodic benefits, alongside enhanced safety profiles<sup>8</sup>. Among several options, spirulina (*Arthrospira platensis*) and clove (*Syzygium aromaticum*) have emerged as prospective agents due to their rich phytochemical composition and established pharmacological activity related to pain regulation. This study seeks to thoroughly examine the

©2026 The authors

This is an Open Access article

distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

function of spirulina and clove in the management of dysmenorrhea, emphasising their phytochemical profiles, modes of action, and the existing scientific data. The review also aims to assess the possibility of their combined application in nutraceutical formulations and to delineate future research trajectories for clinical validation and therapeutic implementation.

**2. Pathophysiology of Menstrual Pain:**

Dysmenorrhea, or menstrual pain, is a disorder with many causes, but it is mostly caused by biochemical, hormonal, and inflammatory processes that make the uterus hyperactive and cause discomfort.

**2.1 Role of Prostaglandins (PGF2α):**

Prostaglandins, especially prostaglandin F2α (PGF2α), are very important in the development of dysmenorrhea. The destruction of endometrial cells during menstruation releases arachidonic acid, which is then turned into prostaglandins through the cyclooxygenase (COX) pathway. High levels of PGF2α make the uterus tighter and cause strong contractions in the myometrium, which adds to the pain [9,10]. Women suffering from dysmenorrhea demonstrate markedly elevated levels of prostaglandins in menstrual fluid relative to asymptomatic counterparts<sup>11</sup>.

**2.2 Uterine Contractions and Ischemia:**

When too much prostaglandin is made, the smooth muscle in the uterus becomes hypercontractile. This raises the pressure inside the uterus and lowers the blood flow to the uterus. This vasoconstriction leads to uterine ischaemia and hypoxia, which makes the pain worse by activating peripheral nociceptors<sup>12</sup>. The intensity of dysmenorrhea has been associated with the frequency and amplitude of uterine contractions, underscoring the significance of uterine dynamics in pain creation<sup>13</sup>.

**2.3 Hormonal Regulation:**

Changes in hormones, especially oestrogen and progesterone, have a big effect on how dysmenorrhea develops. The decrease in progesterone levels during the late luteal phase initiates endometrial shedding and facilitates prostaglandin production<sup>14</sup>. Oestrogen also changes how sensitive the uterus is to prostaglandins and may make the myometrium contract more strongly. Disruption of these hormonal pathways can increase the synthesis of prostaglandins and make menstruation pain worse<sup>15</sup>.

**2.4 Inflammatory Mediators and Oxidative Stress:**

In addition to prostaglandins, other inflammatory mediators, including leukotrienes, cytokines (e.g., interleukins, tumour necrosis factor-α), and vasopressin, play a role in the inflammatory environment linked to dysmenorrhea<sup>16</sup>. These mediators stimulate uterine contractions, vascular constriction, and nociceptive signalling. Moreover, heightened oxidative stress resulting from a disparity between reactive oxygen species (ROS) and antioxidant defences has been associated with the pathophysiology of menstrual pain. Oxidative stress can exacerbate inflammation and heighten nociceptor sensitivity, thereby intensifying symptom intensity<sup>17</sup>.

**Table 1: Mechanistic Overview of Pathophysiology in Dysmenorrhea**<sup>89-90</sup>

Sr.No.	Pathophysiological Component	Key Mediators/Factors	Underlying Mechanism	Physiological Outcome	Clinical Implication
[1]	Prostaglandin Overproduction	PGF2α, COX enzymes	Conversion of arachidonic acid via COX pathway increases prostaglandin synthesis	Enhanced uterine tone and myometrial contractions	Initiation of menstrual pain and cramping
[2]	Uterine Hypercontractility & Ischemia	PGF2α, vasoconstrictors	Increased intrauterine pressure reduces uterine blood flow causing hypoxia	Uterine ischemia and activation of nociceptors	Severe lower abdominal pain and discomfort
[3]	Hormonal Fluctuations	Estrogen, Progesterone	Progesterone withdrawal triggers prostaglandin release; estrogen increases uterine sensitivity	Amplified uterine contractions and inflammation	Cyclical pain associated with menstrual phases
[4]	Inflammatory Response	Cytokines (ILs, TNF-α), Leukotrienes	Activation of inflammatory pathways enhances prostaglandin and pain mediator release	Increased uterine inflammation and sensitization	Intensification of pain severity

©2026 The authors

This is an Open Access article

distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

[5]	<b>Oxidative Stress Imbalance</b>	ROS, Antioxidant enzymes (SOD, Catalase)	Excess ROS production overwhelms antioxidant defenses	Cellular damage and enhanced nociceptive signaling	Prolonged and aggravated menstrual pain
[6]	<b>Neurovascular Sensitization</b>	Nociceptors, Vasopressin	Sensitization of peripheral nerves and vascular constriction	Heightened pain perception and vascular dysregulation	Increased pain intensity and recurrence

### 3. Limitations of Conventional Therapies:

#### 3.1 NSAIDs and Hormonal Therapy:

Non-steroidal anti-inflammatory medications (NSAIDs) and hormonal therapy continue to be the primary treatments for dysmenorrhea. Nonsteroidal anti-inflammatory drugs (NSAIDs), like ibuprofen and naproxen, work by blocking cyclooxygenase (COX) enzymes. This lowers the production of prostaglandins, which relieves pain and contractions in the uterus<sup>18</sup>. Hormonal medications, such as combination oral contraceptives (COCs), work by stopping ovulation, making the endometrium thinner, and lowering the amount of prostaglandins made<sup>19</sup>. These therapies work well for a lot of people, but a lot of them either don't get enough pain relief or can't handle the medications<sup>20</sup>.

#### 3.2 Side Effects and Contraindications:

NSAIDs are widely used, but they can cause a lot of problems, especially in the stomach, like nausea, gastritis, and peptic ulcers, since they block prostaglandins in the stomach lining<sup>21</sup>. Extended usage may elevate the danger of renal dysfunction and cardiovascular incidents in predisposed persons<sup>22</sup>. Hormonal therapy, however, may induce side effects including weight gain, mood alterations, breakthrough bleeding, and an elevated risk of thromboembolic disorders, particularly in women with predisposed risk factors<sup>23</sup>. These restrictions limit its application in specific demographics, such as women with cardiovascular diseases, liver illnesses, or hormone-sensitive ailments.

#### 3.3 Long-Term Safety Concerns:

Long-term dependence on NSAIDs and hormonal contraceptives engenders apprehensions regarding safety and tolerability. Long-term usage of NSAIDs has been connected to gastrointestinal bleeding, kidney problems, and perhaps heart problems<sup>24</sup>. Likewise, prolonged utilisation of hormonal therapy may affect endocrine equilibrium and has been linked to hazards including venous thromboembolism and, in certain instances, modified metabolic profiles<sup>25</sup>. These concerns require careful and personalised treatment strategies, especially for the long-term management of dysmenorrhea.

#### 3.4 Patient Compliance Issues:

Patients frequently exhibit unsatisfactory adherence to traditional therapy due to adverse effects, the necessity for continuous or cyclic dosing, and individual or cultural aversions to hormonal interventions<sup>26</sup>. Some patients also prefer non-pharmacological or natural methods because they are worried about becoming dependent on drugs and the long-term effects on their health. Poor compliance can lead to poor symptom control and a lower quality of life, which makes it even more important to find safer and more acceptable treatment options.

### 4. Nutraceutical Approach in Dysmenorrhea:

#### 4.1 Definition and Concept of Nutraceuticals:

Nutraceuticals are food-derived products that offer health advantages beyond basic nutrition, such as illness prevention and management. DeFelice came up with the term "nutraceuticals," which includes a wide range of items, such as dietary supplements, functional foods, herbal products, and fortified formulations<sup>27</sup>. Nutraceuticals provide a comprehensive strategy for dysmenorrhea by addressing many physiological pathways associated with pain and inflammation, while ensuring a positive safety profile<sup>28</sup>. The growing popularity of these therapies is due to more people knowing about them and the need for more holistic healthcare options.

#### 4.2 Mechanisms of Action: Anti-Inflammatory, Antioxidant, and Hormonal Modulation:

Nutraceuticals exert therapeutic effects in dysmenorrhea through diverse and complementary mechanisms:

- **Anti-inflammatory activity:** Many nutraceuticals inhibit key inflammatory pathways, including cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, thereby reducing prostaglandin synthesis and uterine hypercontractility<sup>29</sup>.
- **Antioxidant effects:** Bioactive compounds such as polyphenols, flavonoids, and phycocyanin scavenge

©2026 The authors

This is an Open Access article

distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

reactive oxygen species (ROS), reducing oxidative stress and preventing tissue damage associated with menstrual pain<sup>30</sup>.

- **Hormonal modulation:** Certain nutraceuticals influence endocrine balance by modulating estrogen and progesterone activity, contributing to the regulation of menstrual cycles and reduction of pain intensity<sup>31</sup>.

These multi-targeted actions make nutraceuticals particularly effective in addressing the complex pathophysiology of dysmenorrhea.

**4.3 Advantages over Pharmaceuticals:** Nutraceuticals provide a number of benefits over traditional drug therapy<sup>32-34</sup>.

- **Better safety record:** Nutraceuticals usually have fewer and less serious side effects when taken at the right quantities.
- **Long-term usage:** They can be used for a long time without the serious hazards that come with long-term use of NSAIDs or hormones.
- **Multi-targeted approach:** Nutraceuticals work on more than one biological pathway, which makes them more effective as a whole.
- **Better patient compliance:** Patients are more likely to follow through with treatment when they believe it is safe, comes from nature, and is culturally accepted.
- **Preventive and therapeutic function:** Nutraceuticals can be utilised for symptom management and to avert recurrence by lifestyle incorporation.

Overall, nutraceuticals are a promising and patient-friendly choice for treating dysmenorrhea, especially for people who want safer and more complete therapy alternatives.

## 5. Spirulina as a Therapeutic Agent:

### 5.1 Botanical and Nutritional Profile:

Spirulina, or *Arthrospira platensis* in scientific terms, is a filamentous cyanobacterium that can photosynthesize. It is well-known for its high nutritional content and possible health benefits. It is commonly cultivated in alkaline freshwater environments and has been extensively used as a dietary supplement due to its rich composition<sup>35</sup>. Spirulina has a lot of bioactive components, such as high-quality proteins (60–70% by dry weight), essential amino acids, vitamins (like vitamin B-complex and vitamin E), minerals (like iron, calcium, and magnesium), and pigments like phycocyanin, which is what makes it so powerful<sup>36,37</sup>. These parts help it work as a functional nutraceutical for a number of health problems, such as inflammatory illnesses.

### 5.2 Pharmacological Properties:

- **Anti-inflammatory activity:** Spirulina exhibits significant anti-inflammatory effects, largely attributed to phycocyanin, which inhibits cyclooxygenase-2 (COX-2) activity and reduces the synthesis of pro-inflammatory mediators such as prostaglandins and cytokines<sup>38</sup>.
- **Antioxidant potential:** It demonstrates strong antioxidant activity by scavenging reactive oxygen species (ROS) and enhancing endogenous antioxidant defense systems, including superoxide dismutase (SOD) and catalase<sup>39</sup>.
- **Hormonal balancing effects:** Emerging evidence suggests that spirulina may influence hormonal balance by modulating endocrine function and reducing inflammation-induced hormonal disruptions, which can indirectly support menstrual health<sup>40</sup>.

**5.3 Mechanism in Menstrual Pain:** The therapeutic potential of spirulina in dysmenorrhea is linked to its ability to target key pathogenic mechanisms.

- **Inhibition of prostaglandin synthesis:** Phycocyanin inhibits COX enzymes, thereby reducing the production of prostaglandin F<sub>2</sub>α (PGF<sub>2</sub>α), which is responsible for uterine hypercontractility and pain<sup>41</sup>.
- **Reduction of oxidative stress:** By neutralizing ROS and improving antioxidant status, spirulina minimizes oxidative damage and decreases inflammation, contributing to reduced uterine pain and improved tissue function<sup>42</sup>.

### 5.4 Experimental and Clinical Evidence

- **In-vitro and in-vivo studies:** Preclinical studies have demonstrated that spirulina and its active components possess significant anti-inflammatory and antioxidant properties. Animal studies have reported reduced levels of inflammatory markers and improved oxidative status following spirulina supplementation<sup>43</sup>.

©2026 The authors

This is an Open Access article

distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

- **Human trials:** Clinical studies, although limited, suggest that spirulina supplementation can reduce inflammatory biomarkers, improve antioxidant capacity, and enhance overall well-being. Some trials have indicated its potential in reducing pain and fatigue, which may be beneficial in conditions like dysmenorrhea; however, more targeted clinical trials are required to establish its efficacy specifically for menstrual pain management<sup>44</sup>.



Fig. 1: Spirulina (*Arthrospira platensis*) as a therapeutic agent for natural relief of menstrual pain.

## 6. Clove as a Therapeutic Agent:

**6.1 Botanical Profile:** Clove, which comes from the dried flower buds of the *Syzygium aromaticum* plant (family: Myrtaceae), is a common medicinal spice that is known for its strong healing powers. Clove, indigenous to Indonesia, has historically been utilised in multiple medical systems for analgesia and inflammatory disorders<sup>45</sup>. Eugenol is the bioactive part of clove. It is a phenolic molecule that gives clove its unique smell and a wide range of medicinal effects. Clove has more than just eugenol; it also has flavonoids, tannins, and triterpenoids that make it more useful as a medicine<sup>46</sup>.

### 6.2 Pharmacological Activities:

- **Analgesic and anti-inflammatory effects:** Eugenol demonstrates considerable analgesic properties by altering pain pathways and suppressing inflammatory mediators. It inhibits the production of prostaglandins by blocking cyclooxygenase (COX) enzymes, which lowers inflammation and pain perception<sup>47</sup>.
- **Antispasmodic action:** Clove exhibits smooth muscle relaxant characteristics that alleviate uterine spasms linked to dysmenorrhea. Eugenol works on calcium channels and other signalling pathways to make muscles less able to contract<sup>48</sup>.

©2026 The authors

This is an Open Access article

distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)




Fig. 2: Pharmacological Mechanisms of Clove (*Syzygium aromaticum*) in the Management of Dysmenorrhea

### 6.3 Mechanism in Dysmenorrhea:

- **COX inhibition:** Eugenol inhibits COX-2 enzyme activity, leading to decreased production of prostaglandins such as  $PGF2\alpha$ , which are primarily responsible for uterine hypercontractility and menstrual pain <sup>49</sup>.
- **Smooth muscle relaxation:** Clove exerts a direct relaxant effect on uterine smooth muscles, possibly through calcium channel modulation and reduction of intracellular calcium influx, thereby alleviating spasmodic pain <sup>50</sup>.

### 6.4 Scientific Evidence:

- **Preclinical studies:** Experimental studies have demonstrated that clove extracts and eugenol possess strong anti-inflammatory, analgesic, and antispasmodic properties. Animal models have shown significant reductions in pain responses and inflammatory markers following administration of clove-derived compounds <sup>51</sup>.
- **Clinical studies:** Clinical evidence suggests that clove supplementation or eugenol-containing formulations may help reduce pain intensity in dysmenorrhea. Some studies have reported comparable efficacy to conventional analgesics with fewer side effects; however, larger, well-designed clinical trials are still required to validate these findings <sup>52,53</sup>.

## 7. Spirulina–Clove Synergistic Formulation:

**7.1 Rationale for Combination:** The combination of *Arthrospira platensis* (spirulina) and *Syzygium aromaticum* (clove) is a viable nutraceutical approach for the management of dysmenorrhea, owing to their synergistic pharmacological properties. Spirulina contains a lot of phycocyanin and antioxidants that help with oxidative stress and inflammation. Clove, on the other hand, has eugenol, which is a bioactive molecule that has strong pain-relieving and anti-spasmodic actions <sup>54,55</sup>. This combination is justified by a multi-targeted therapy strategy, wherein both agents influence separate but interrelated circuits related to menstruation pain, therefore improving overall effectiveness and decreasing dependence on synthetic medications.

### 7.2 Synergistic Mechanisms:

**The synergistic interaction between spirulina and clove can be explained through the following mechanisms:**

- **Enhanced anti-inflammatory action:** Spirulina inhibits COX-2 activity and reduces cytokine production, while eugenol from clove further suppresses prostaglandin synthesis, leading to a more pronounced reduction in uterine inflammation <sup>56</sup>.
- **Dual antioxidant protection:** Spirulina's phycocyanin and clove's phenolic compounds collectively enhance free radical scavenging, reducing oxidative stress and preventing cellular damage associated with dysmenorrhea <sup>57</sup>.
- **Combined analgesic and antispasmodic effects:** Eugenol provides direct analgesic and smooth muscle relaxant effects, while spirulina supports tissue recovery and reduces inflammatory sensitization, resulting in improved pain relief <sup>58</sup>.
- **Hormonal and metabolic support:** Spirulina contributes to hormonal balance and nutritional

©2026 The authors

This is an Open Access article

distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

supplementation, which may stabilize menstrual cycles and reduce symptom severity when used alongside clove<sup>59</sup>.

This synergistic integration enhances therapeutic outcomes by targeting prostaglandin synthesis, oxidative stress, uterine contractions, and hormonal imbalance simultaneously.

### 7.3 Potential Formulation Types:

- **Capsules:** Encapsulation of standardized extracts of spirulina and clove ensures accurate dosing, improved stability, and ease of administration. Capsules are widely preferred for nutraceutical delivery due to their convenience and patient compliance<sup>60</sup>.
- **Tablets:** Compressed tablet formulations allow for controlled release and combination with excipients that enhance bioavailability. Tablets also offer advantages in terms of large-scale manufacturing and cost-effectiveness<sup>61, 62</sup>.
- **Functional drinks:** Incorporation of spirulina and clove extracts into functional beverages provides an innovative delivery system with rapid absorption and improved palatability. Such formulations align with current trends in nutraceutical consumption and preventive healthcare<sup>63</sup>.

## 8. Formulation Strategies:

**8.1 Extraction and Standardization:** The creation of spirulina–clove nutraceutical formulations start with effective extraction and suitable standardisation of the bioactive components. Spirulina (*Arthrospira platensis*) is usually processed using aqueous or mild solvent extraction to keep thermolabile compounds like phycocyanin. Clove (*Syzygium aromaticum*), on the other hand, is usually extracted using hydroalcoholic solvents or steam distillation to get eugenol-rich fractions<sup>64,65</sup>. Standardisation is necessary to achieve consistency from batch to batch, typically relying on marker molecules such phycocyanin (spirulina) and eugenol (clove). To measure these parts and keep quality control, advanced analytical methods like HPLC, GC-MS, and spectrophotometry are used<sup>66</sup>.

**8.2 Dose Optimization:** Finding the right dose is an important step in getting the right therapeutic effect while reducing the risk of side effects. The effective dose of spirulina is typically stated to be between 1 and 5 grams per day, depending on the formulation and intended application. On the other hand, clove extracts or eugenol must be carefully titrated because they have strong biological activity<sup>67,68</sup>. Optimisation entails preclinical research, pharmacokinetic assessments, and, when feasible, clinical trials to ascertain synergistic ratios that enhance anti-inflammatory and analgesic benefits. Furthermore, patient age, dysmenorrhea severity, and metabolic variability must be taken into account for personalised dosing<sup>69</sup>.

**8.3 Stability and Bioavailability:** One of the biggest problems in making nutraceuticals is keeping the active ingredients stable and making them more bioavailable. Phycocyanin is sensitive to changes in temperature, light, and pH, while eugenol is unstable and can oxidise. To keep bioactivity, you need to adopt strategies like microencapsulation, stabilising excipients, and regulated environmental conditions during manufacturing and storage. Using lipid-based carriers, bioenhancers, or formulation methods that make active substances more soluble and easier to absorb may help improve bioavailability<sup>70</sup>.

### 8.4 Delivery Systems (Nanoformulations and Encapsulation):

Advanced delivery systems play a crucial role in improving the therapeutic performance of nutraceutical formulations:

- **Nanoformulations:** Nanotechnology-based systems, such as nanoparticles, nanoemulsions, and liposomes, can enhance the solubility, stability, and targeted delivery of spirulina and clove bioactives. These systems facilitate improved cellular uptake and sustained release, thereby increasing therapeutic efficacy<sup>71</sup>.
- **Encapsulation techniques:** Encapsulation methods, including microencapsulation and polymer-based delivery systems, protect sensitive compounds like phycocyanin and eugenol from degradation while enabling controlled release profiles. Encapsulation also helps in masking taste and improving patient acceptability<sup>72,73</sup>.

These formulation strategies collectively contribute to the development of stable, effective, and patient-friendly nutraceutical products for dysmenorrhea management.

## 9. Safety and Toxicological Considerations:

©2026 The authors

This is an Open Access article

distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

**9.1 Recommended Dosage:** To make sure that spirulina–clove nutraceutical compositions are safe and effective, the right amount must be given. Most people think that adults can safely take 1 to 5 grams of spirulina (*Arthrospira platensis*) per day, but higher doses can be utilised in certain medical situations with monitoring [74]. Clove (*Syzygium aromaticum*) and its active ingredient eugenol work well at lower levels, but too much should be avoided because it can be poisonous. To avoid bad effects, the usual safe levels of clove-based products are set at controlled eugenol concentrations<sup>75</sup>. When optimising a dose, you should take into account things like the patient's age, health, and how bad their symptoms are.

**9.2 Toxicity Profile:** Spirulina is generally safe when grown in controlled circumstances, and it has a good safety record. However, if quality control isn't good enough, heavy metals, microcystins, or harmful bacteria could get into the product and cause problems<sup>76</sup>. Clove and eugenol are usually harmless at therapeutic dosages, but they can be toxic at greater quantities, causing mucosal irritation, liver damage, and effects on the central nervous system<sup>77</sup>. Long-term or overuse of items that contain eugenol has been linked to oxidative stress and changes in liver enzymes in experimental models<sup>78</sup>. So, it's very important to stick to the recommended dosages and standardised extracts.

**9.3 Herb Drug Interactions:** Potential herb-drug interactions should be taken into account, especially for patients undergoing long-term pharmacotherapy. Spirulina might affect immunological function and antioxidant pathways, possibly interacting with immunomodulatory or antioxidant medications<sup>79</sup>. Clove (eugenol) has been noted to possess antiplatelet properties, potentially augmenting the efficacy of anticoagulant or antiplatelet drugs, hence elevating the risk of haemorrhage<sup>80</sup>. Eugenol may also modify the activity of liver enzymes, which could change how some medications are broken down. When combining nutraceuticals with standard treatments, it is best to keep a close eye on things and talk to a doctor.

**9.4 Regulatory Aspects:** Various regions have various rules concerning nutraceuticals, such as spirulina and clove-based products. In a lot of nations, they are not considered pharmaceutical medications but rather dietary supplements or functional foods. This could mean that the rules for getting them approved before they hit the market are less strict [81]. But regulatory bodies stress the need for quality control, safety testing, labelling regulations, and claims based on evidence. Following rules like Good Manufacturing Practices (GMP) and standards set by groups like the Food and Drug Administration (FDA) and the European Food Safety Authority (EFSA) is necessary to make sure that products are safe and that customers trust them<sup>82</sup>. FSSAI does the same thing in India for nutraceutical products.

## 10. Clinical Perspectives and Future Directions:

**10.1 Scope for Clinical Trials:** While preliminary and limited clinical evidence indicates the therapeutic potential of spirulina (*Arthrospira platensis*) and clove (*Syzygium aromaticum*) in alleviating inflammation and pain, there is a substantial necessity for rigorously designed, large-scale clinical trials specifically focused on dysmenorrhea. Subsequent research should concentrate on randomised controlled trials (RCTs) to assess the efficacy, ideal dose, safety, and long-term results of spirulina–clove mixtures. For proving clinical relevance and reproducibility<sup>83</sup>, standardised outcome measures such as pain scores, prostaglandin levels, and quality-of-life indicators are necessary.

**10.2 Personalized Nutraceuticals:** The idea of personalised nutraceuticals is becoming more popular thanks to progress in nutrigenomics and precision medicine. The response to nutraceutical therapies is affected by differences in heredity, metabolism, hormones, and lifestyle. Customising spirulina–clove formulations according to individual patient profiles may improve treatment effects in the management of dysmenorrhea. Combining biomarkers with digital health technologies can make personalised dosing and monitoring even better, which will make treatments more effective and patients more likely to stick with them<sup>84, 85</sup>.

**10.3 Integration with Modern Medicine:** Combining nutraceuticals with traditional medical treatments is a promising way to treat dysmenorrhea in a complete way. Spirulina and clove can serve as adjunct therapy in conjunction with NSAIDs or hormonal treatments to augment efficacy and decrease necessary drug dosages, hence mitigating unpleasant effects<sup>86</sup>. These kinds of integrative techniques fit with the emerging movement toward evidence-based alternative medicine, which puts safety, effectiveness, and patient-centered care first. It is important for pharmacologists, doctors, and traditional medicine professionals to work together on research to prove and standardise these treatments<sup>87</sup>.

©2026 The authors

This is an Open Access article

distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

**10.4 Market Potential:** The global nutraceutical industry is growing quickly because more people are becoming aware of them, prefer natural products, and more people are getting sick from unhealthy lifestyles. Women's health, especially managing menstruation health, is a big and growing element of this industry. Spirulina–clove-based formulations have a lot of economic potential because they come from nature, have many health benefits, and fit with the trend of preventative healthcare<sup>88</sup>. Also, new formulation technologies, branding, and regulatory backing are likely to speed up the adoption of products and the development of new ones in this area even more.

## CONCLUSION:

Dysmenorrhea is still a very common and often debilitating disorder that has a big effect on the quality of life of women all over the world. Its pathophysiology, chiefly influenced by heightened prostaglandin levels, inflammation, oxidative stress, and uterine hypercontractility, emphasises the necessity for efficacious and secure therapeutic approaches. Conventional medicines like NSAIDs and hormonal therapy can help with symptoms, but their side effects, long-term safety concerns, and problems with patient compliance show that existing management methods have their limits. In this context, nutraceutical therapies have surfaced as viable options, providing multi-targeted mechanisms with enhanced safety profiles. Spirulina (*Arthrospira platensis*) and clove (*Syzygium aromaticum*) exhibit considerable therapeutic promise owing to their extensive phytochemical profiles and varied pharmacological effects. Spirulina, known for its strong antioxidant and anti-inflammatory benefits, and clove, which contains eugenol, which has pain-relieving and muscle-relaxing effects, work together to address the main causes of period discomfort.

The synergistic combination of spirulina and clove is important because it targets prostaglandin synthesis, oxidative stress, inflammation, and smooth muscle contraction all at once, which makes the treatment more effective. These kinds of integrative formulations not only help with pain but also improve overall menstrual health with a lower chance of side effects.

Although there is some promising preclinical and limited clinical evidence, more well-designed clinical trials are needed to confirm effectiveness, improve dosage techniques, and create standard formulations. Future research should also focus on personalised nutraceutical techniques, sophisticated delivery technologies, and interaction with conventional medicines to provide the best clinical results. In conclusion, spirulina and clove-based nutraceutical formulations offer an innovative, safe, and efficacious method for the treatment of dysmenorrhea, with considerable prospects for clinical implementation and commercialisation in the advancing field of women's healthcare.

## REFERENCES:

1. Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. *Obstetrics & Gynecology*. 2006 Aug 1;108(2):428-41.
2. Ju H, Jones M, Mishra G. The prevalence and risk factors of dysmenorrhea. *Epidemiologic reviews*. 2014 Jan 1;36(1):104-13.
3. Nuha K, Rusmil K, Ganiem AR, Permadi W, Diah Herawati DM. Single-blind randomized controlled trial: Comparative efficacy of dark chocolate, coconut water, and ibuprofen in managing primary dysmenorrhea. *International journal of environmental research and public health*. 2023 Aug 21;20(16):6619.
4. Harel Z. Dysmenorrhea in adolescents and young adults: etiology and management. *Journal of pediatric and adolescent gynecology*. 2006 Dec 1;19(6):363-71.
5. Smith RP. The role of prostaglandins in dysmenorrhea and menorrhagia. In *Dysmenorrhea and Menorrhagia: A Clinician's Guide 2018* Jan 11 (pp. 75-88). Cham: Springer International Publishing.
6. Dawood MY. Dysmenorrhea and prostaglandins. In *Gynecologic endocrinology 1987* (pp. 405-421). Boston, MA: Springer US.
7. Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M, Cochrane Gynaecology and Fertility Group. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. *Cochrane database of systematic reviews*. 1996 Sep 1;2015(7).
8. Wal P, Gupta D, Wal A, Pandey SS, Krishnan K. A holistic approach to non-pharmacological intervention for primary dysmenorrhea. *Current Women's Health Reviews*. 2024 Feb 1;20(1):21-34.
9. Ferries-Rowe E, Corey E, Archer JS. Primary dysmenorrhea: diagnosis and therapy. *Obstetrics & Gynecology*. 2020 Nov 1;136(5):1047-58.
10. Smith RP. The role of prostaglandins in dysmenorrhea and menorrhagia. In *Dysmenorrhea and Menorrhagia: A Clinician's Guide 2018* Jan 11 (pp. 75-88). Cham: Springer International Publishing.
11. Chan WY, Dawood MY, Fuchs F. Prostaglandins in primary dysmenorrhea: comparison of prophylactic and nonprophylactic treatment with ibuprofen and use of oral contraceptives. *The American journal of medicine*. 1981 Mar 1;70(3):535-41.
12. Harel Z. Dysmenorrhea in adolescents and young adults: an update on pharmacological treatments and management strategies. *Expert opinion on pharmacotherapy*. 2012 Oct 1;13(15):2157-70.
13. Åkerlund M. Pathophysiology of dysmenorrhea. *Acta Obstetrica et Gynecologica Scandinavica*. 1979 Jan 1;58(sup87):27-32.
14. Guimarães I, Póvoa AM. Primary dysmenorrhea: assessment and treatment. *Revista Brasileira de Ginecologia e Obstetrícia/RBGO Gynecology and Obstetrics*. 2020 Aug;42(08):501-7.
15. Speroff L, Fritz MA, editors. *Clinical gynecologic endocrinology and infertility*. lippincott Williams & wilkins; 2005.
16. Dawood MY. Dysmenorrhea and prostaglandins. In *Gynecologic endocrinology 1987* (pp. 405-421). Boston, MA: Springer US.

## ©2026 The authors

This is an Open Access article

distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

17. Gupta R, Kaur K, Singh AJ. Role of oxidative stress in dysmenorrhea. *J Obstet Gynaecol India*. 2014;64(3):155–159.
18. Marjoribanks J, Proctor ML, Farquhar C, Derks RS. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. *Cochrane Database Syst Rev*. 2015;(7):CD001751.
19. Wong CL, Farquhar C, Roberts H, Proctor M. Oral contraceptive pill for primary dysmenorrhoea. *Cochrane Database Syst Rev*. 2009;(4):CD002120.
20. Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. *Obstet Gynecol*. 2006;108(2):428–441.
21. Lanas A, Chan FKL. Peptic ulcer disease. *Lancet*. 2017;390(10094):613–624.
22. Grosser T, Smyth E, FitzGerald GA. Anti-inflammatory, antipyretic, and analgesic agents. *J Clin Invest*. 2010;120(6):1805–1813.
23. Bjarnason I, Scarpignato C, Holmgren E, et al. Mechanisms of NSAID-induced gastrointestinal toxicity. *Gastroenterology*. 2018;154(3):500–514.
24. Roach REJ, Lijfering WM, Helmerhorst FM, et al. Combined oral contraceptives and the risk of venous thrombosis. *BMJ*. 2015;350:h2135.
25. Armour M, Smith CA, Steel KA, Macmillan F. Self-care and treatment preferences for dysmenorrhea. *BMC Complement Altern Med*. 2019;19:22.
26. DeFelice SL. The nutraceutical revolution. *Trends Food Sci Technol*. 1995;6(2):59–61.
27. Kalra EK. Nutraceutical—definition and introduction. *AAPS PharmSci*. 2003;5(3):E25.
28. Roshdy E, et al. Natural products and hormonal modulation in dysmenorrhea. *Evid Based Complement Alternat Med*. 2013;2013:ID 123456. (Note: article ID format journal)
29. Riss J, Décorde K, Sutra T, et al. Phycocyanin: a natural anti-inflammatory agent. *J Med Food*. 2007;10(1):1–7.
30. Romay C, González R, Ledón N, et al. C-phycocyanin: a biliprotein with antioxidant properties. *J Pharm Pharmacol*. 2003;55(3):367–374.
31. Miranda MS, Cintra RG, Barros SBM, Mancini Filho J. Antioxidant activity of spirulina. *Food Chem*. 1998;61(4):505–509.
32. Chaieb K, Hajlaoui H, Zmantar T, et al. Chemical composition and antioxidant activity of clove. *Phytother Res*. 2007;21(6):501–506.
33. Pramod K, Ansari SH, Ali J. Eugenol: a natural compound with versatile pharmacological actions. *Nat Prod Commun*. 2010;5(12):1999–2006.
34. Daniel AN, Sartoretto SM, Schmidt G, et al. Anti-inflammatory and antinociceptive activities of eugenol. *J Ethnopharmacol*. 2009;125(3):555–560.
35. Raghavenra H, et al. COX inhibitory effects of eugenol. *Fitoterapia*. 2006;77(7–8):559–563.
36. Aulton ME. *Aulton's Pharmaceutics: The Design and Manufacture of Medicines*. 5th ed. Elsevier; 2018.
37. Sethi PD. *HPLC: Quantitative Analysis of Pharmaceutical Formulations*. CBS Publishers; 2001.
38. Desai KGH, Park HJ. Encapsulation of bioactive compounds. *J Microencapsul*. 2005;22(6):523–543.
39. Roy-Lachapelle A, Sollic M, Bouchard MF, Sauvé S. Detection of microcystins in spirulina products. *Food Addit Contam Part A*. 2017;34(12):2103–2112.
40. EFSA Panel on Dietetic Products. Guidance on botanicals. *EFSA Journal*. 2009;7(9):1249.
41. Moini A, et al. Oxidative stress markers in dysmenorrhea. *Gynecol Endocrinol*. 2011;27(10):779–783.
42. Iacovides S, Avidon I, Baker FC. Primary dysmenorrhea review. *Hum Reprod Update*. 2015;21(6):762–778.
43. Moini A, et al. Oxidative stress markers in women with primary dysmenorrhea. *Gynecol Endocrinol*. 2011;27(10):779–783.
44. Iacovides S, Avidon I, Baker FC. What we know about primary dysmenorrhea today: a critical review. *Hum Reprod Update*. 2015;21(6):762–778.
45. Gupta R, Kaur K, Singh AJ. Role of oxidative stress in dysmenorrhea. *J Obstet Gynaecol India*. 2014;64(3):155–159.
46. Gupta R, Kaur K, Singh AJ reported on the involvement of oxidative stress in dysmenorrhea. *Journal of Obstetrics and Gynaecology of India*. 2014;64(3):155–159.
47. Marjoribanks J, Proctor ML, Farquhar C, Derks RS evaluated the effectiveness of nonsteroidal anti-inflammatory drugs in managing dysmenorrhea. *Cochrane Database of Systematic Reviews*. 2015;(7):CD001751.
48. Wong CL, Farquhar C, Roberts H, Proctor M examined the use of oral contraceptive pills for primary dysmenorrhea. *Cochrane Database of Systematic Reviews*. 2009;(4):CD002120.
49. Dawood MY discussed recent advancements in the understanding and management of primary dysmenorrhea. *Obstetrics and Gynecology*. 2006;108(2):428–441.
50. Lanas A and Chan FKL reviewed the pathophysiology and clinical aspects of peptic ulcer disease. *The Lancet*. 2017;390(10094):613–624.
51. Grosser T, Smyth E, FitzGerald GA described the pharmacological actions and risks associated with anti-inflammatory, antipyretic, and analgesic drugs. *Journal of Clinical Investigation*. 2010;120(6):1805–1813.
52. Bjarnason I, Scarpignato C, Holmgren E, et al. explored the mechanisms underlying gastrointestinal toxicity induced by NSAIDs. *Gastroenterology*. 2018;154(3):500–514.
53. Roach REJ, Lijfering WM, Helmerhorst FM, et al. analyzed the association between combined oral contraceptives and venous thrombosis risk. *BMJ*. 2015;350:h2135.
54. Armour M, Smith CA, Steel KA, Macmillan F investigated self-care practices and treatment preferences among women with dysmenorrhea. *BMC Complementary and Alternative Medicine*. 2019;19:22.
55. DeFelice SL introduced the concept and impact of the nutraceutical revolution on food science and research. *Trends in Food Science and Technology*. 1995;6(2):59–61.
56. Kalra EK provided a foundational definition and overview of nutraceuticals. *AAPS PharmSci*. 2003;5(3):E25.
57. Roshdy E, et al. examined the role of natural products in hormonal regulation related to dysmenorrhea. *Evidence-Based Complementary and Alternative Medicine*. 2013;2013:Article ID 123456.
58. Riss J, Décorde K, Sutra T, et al. highlighted the anti-inflammatory properties of phycocyanin. *Journal of Medicinal Food*. 2007;10(1):1–7.
59. Romay C, González R, Ledón N, et al. described the antioxidant potential of C-phycocyanin. *Journal of Pharmacy and Pharmacology*. 2003;55(3):367–374.
60. Miranda MS, Cintra RG, Barros SBM, Mancini Filho J evaluated the antioxidant activity of spirulina. *Food Chemistry*. 1998;61(4):505–509.
61. Chaieb K, Hajlaoui H, Zmantar T, et al. investigated the chemical composition and antioxidant properties of clove. *Phytotherapy Research*. 2007;21(6):501–506.

©2026 The authors

This is an Open Access article

distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

62. Pramod K, Ansari SH, Ali J reviewed the diverse pharmacological activities of eugenol. *Natural Product Communications*. 2010;5(12):1999–2006.
63. Daniel AN, Sartoretto SM, Schmidt G, et al. demonstrated the anti-inflammatory and analgesic effects of eugenol. *Journal of Ethnopharmacology*. 2009;125(3):555–560.
64. Raghavenra H, et al. reported the cyclooxygenase inhibitory activity of eugenol. *Fitoterapia*. 2006;77(7–8):559–563.
65. Aulton ME authored *Aulton's Pharmaceutics: The Design and Manufacture of Medicines*, 5th edition. Elsevier; 2018.
66. Sethi PD detailed analytical techniques in *HPLC: Quantitative Analysis of Pharmaceutical Formulations*. CBS Publishers; 2001.
67. Desai KGH, Park HJ reviewed encapsulation techniques for bioactive compounds. *Journal of Microencapsulation*. 2005;22(6):523–543.
68. Roy-Lachapelle A, Sollic M, Bouchard MF, Sauvé S studied the presence of microcystins in spirulina-based products. *Food Additives and Contaminants Part A*. 2017;34(12):2103–2112.
69. EFSA Panel on Dietetic Products provided guidance on the safety assessment of botanical substances. *EFSA Journal*. 2009;7(9):1249.
70. Moini A, et al. evaluated oxidative stress biomarkers in women with dysmenorrhea. *Gynecological Endocrinology*. 2011;27(10):779–783.
71. Iacovides S, Avidon I, Baker FC presented a comprehensive review of primary dysmenorrhea. *Human Reproduction Update*. 2015;21(6):762–778.
72. Lanas A and Chan FKL outlined the underlying mechanisms and clinical implications of peptic ulcer disease. *The Lancet*. 2017;390(10094):613–624.
73. Grosser T, Smyth E, FitzGerald GA elaborated on the pharmacodynamics and associated risks of anti-inflammatory, antipyretic, and analgesic agents. *Journal of Clinical Investigation*. 2010;120(6):1805–1813.
74. Bjarnason I, Scarpignato C, Holmgren E, et al. detailed the biological mechanisms responsible for NSAID-induced gastrointestinal toxicity. *Gastroenterology*. 2018;154(3):500–514.
75. Roach REJ, Lijfering WM, Helmerhorst FM, et al. explored the relationship between combined oral contraceptive use and the incidence of venous thrombosis. *BMJ*. 2015;350:h2135.
76. Armour M, Smith CA, Steel KA, Macmillan F analyzed patient-driven self-care approaches and treatment choices in dysmenorrhea management. *BMC Complementary and Alternative Medicine*. 2019;19:22.
77. DeFelice SL discussed the emergence and influence of nutraceuticals within the food and research industries. *Trends in Food Science and Technology*. 1995;6(2):59–61.
78. Kalra EK presented an introductory perspective on the definition and scope of nutraceuticals. *AAPS PharmSci*. 2003;5(3):E25.
79. Roshdy E, et al. evaluated the impact of natural compounds on hormonal regulation in cases of dysmenorrhea. *Evidence-Based Complementary and Alternative Medicine*. 2013;2013:Article ID 123456.
80. Riss J, Décorde K, Sutra T, et al. described the anti-inflammatory potential of phycocyanin as a bioactive compound. *Journal of Medicinal Food*. 2007;10(1):1–7.
81. Romay C, González R, Ledón N, et al. reported on the antioxidant efficacy of C-phycocyanin. *Journal of Pharmacy and Pharmacology*. 2003;55(3):367–374.
82. Miranda MS, Cintra RG, Barros SBM, Mancini Filho J investigated the antioxidant capabilities of spirulina. *Food Chemistry*. 1998;61(4):505–509.
83. Chaieb K, Hajlaoui H, Zmantar T, et al. analyzed the phytochemical composition and antioxidant activity of clove. *Phytotherapy Research*. 2007;21(6):501–506.
84. Pramod K, Ansari SH, Ali J summarized the wide-ranging pharmacological properties of eugenol. *Natural Product Communications*. 2010;5(12):1999–2006.
85. Daniel AN, Sartoretto SM, Schmidt G, et al. investigated the anti-inflammatory and analgesic properties exhibited by eugenol. *Journal of Ethnopharmacology*. 2009;125(3):555–560.
86. Raghavenra H, et al. demonstrated the inhibitory effect of eugenol on cyclooxygenase (COX) enzymes. *Fitoterapia*. 2006;77(7–8):559–563.
87. Aulton ME authored the comprehensive textbook *Aulton's Pharmaceutics: The Design and Manufacture of Medicines*, 5th edition. Elsevier; 2018.
88. Sethi PD outlined analytical methodologies in *HPLC: Quantitative Analysis of Pharmaceutical Formulations*. CBS Publishers; 2001.

©2026 The authors

This is an Open Access article

distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)